

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
November 6, 2019

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Ward Brown, M.D.	No
3	Catherine Decker, Pharm.D.	No
4	John Fangman, M.D.	Yes
5	Kevin Izard, M.D.	Yes – arrived @9:50am
6	Steve Maike, RPh	Yes
7	William E. Raduege, M.D.	Yes
8	Robert Rohloff, M.D.	No
9	Pat Towers	Yes – arrived @9:25am
10	Alicia Walker, Pharm.D.	No
11	Michael Witkovsky, M.D.	Yes – arrived @9:30am

NOVEMBER 2019 THERAPEUTIC DRUG CLASS

ALZHEIMER'S AGENTS
ANTICONVULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRIs
ANTI-HISTAMINES, MINIMALLY SEDATING
ANTI-HYPERTENSIVES, SYMPATHOLYTIC
ANTI-HYPERURICEMICS, ORAL
ANTI-PARKINSON'S AGENTS
ANTI-PSORIATICS, ORAL
ANTI-PSORIATICS, TOPICAL
ANTI-PSYCHOTICS
ANXIOLYTICS
BILE SALTS
BRONCHODILATORS, BETA AGONIST
COPD AGENTS
COUGH AND COLD/NARCOTICS
CYTOKINE AND CAM ANTAGONISTS
EPINEPHRINE, SELF-INJECTED
ERYTHROPOIESIS STIMULATING PROTEINS
GLUCOCORTICOIDS, INHALED
GLUCOCORTICOIDS, ORAL
HISTAMINE II RECEPTOR BLOCKERS
IMMUNOMODULATORS FOR ATOPIC DERMATITIS
IMMUNOMODULATORS, TOPICAL
INTRANASAL RHINITIS AGENTS
LEUKOTRIENE MODIFIERS
METHOTREXATE
NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)
NSAIDS
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS
OPHTHALMIC ANTI-INFLAMMATORIES
OPHTHALMIC ANTI-INFLAMMATORIES/IMMUNOMODULATORS
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES
SEDATIVE HYPNOTICS
STERIODS, TOPICAL-HIGH POTENCY
STERIODS, TOPICAL-LOW POTENCY
STERIODS, TOPICAL-MEDIUM POTENCY
STERIODS, TOPICAL-VERY HIGH POTENCY
STIMULANTS AND RELATED AGENTS

Recommendations Summary:

The following drug classes presented for review had no recommended changes since the November 7, 2018 Wisconsin Medicaid Pharmacy PA Advisory Committee (PAC) meeting and were approved by the PAC in a block vote.

Drug Classes included in the committee block vote:

- Alzheimer's Agents
 - Antidepressants, SSRIs
 - Antihistamines, Minimally Sedating
 - Antihypertensives, Sympatholytics
 - Antipsoriatics, Oral
 - Anxiolytics
 - Bile Salts
 - Cough and Cold, Narcotic
 - Histamine II Receptor Blocker
 - Immunomodulators, Topical
 - Leukotriene Modifiers
 - Methotrexate
 - Ophthalmic Antibiotic-Steroid Combinations
 - Ophthalmic Antibiotics
 - Ophthalmics for Allergic Conjunctivitis
 - Otic Anti-Infectives & Anesthetics
 - Otic Antibiotics
 - Steroids, Topical Low
 - Steroids, Topical Medium
-
- Discussion: None
 - William Raduege made a motion to accept staff recommendations as presented.
 - Second – John Fangman
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid ANTICONSULSANTS		Recommendations				
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRIMIDONE (AG) (ORAL)	0.0%	P	P			
TOPIRAMATE ER (QUDEXY) (AG) (ORAL)	0.0%	NP	NP			
GABITRIL (ORAL)	0.0%	P	P			
FELBATOL SUSPENSION (ORAL)	0.0%	NP	NP			
CLONAZEPAM (ORAL)	18.8%	P	P			
LAMOTRIGINE TABLET (ORAL)	21.4%	P	P			
TOPIRAMATE TABLETS (ORAL)	14.1%	P	P			
PRIMIDONE (ORAL)	1.0%	P	P			
DIVALPROEX TABLET (ORAL)	4.4%	P	P			
CELONTIN (ORAL)	0.0%	P	P			
VALPROIC ACID SOLUTION (ORAL)	1.0%	P	P			
LEVETIRACETAM TABLETS (ORAL)	8.0%	P	P			
TEGRETOL SUSPENSION (ORAL)	0.1%	P	P			
TEGRETOL TABLET (ORAL)	1.2%	P	P			
ZONISAMIDE (ORAL)	1.9%	P	P			
LEVETIRACETAM SOLUTION (ORAL)	2.8%	P	P			
OXCARBAZEPINE TABLETS (ORAL)	3.9%	P	P			
FELBATOL TABLET (ORAL)	0.1%	NP	NP			
PHENYTOIN SUSPENSION (ORAL)	0.1%	P	P			
VALPROIC ACID CAPSULE (ORAL)	0.1%	P	P			
PEGANONE (ORAL)	0.0%	P	P			
LAMOTRIGINE DISPERSIBLE TABLET (ORAL)	0.5%	P	P			
DIVALPROEX ER (ORAL)	6.5%	P	P			
CARBAMAZEPINE TABLET (ORAL)	0.1%	NP	NP			
LEVETIRACETAM ER (ORAL)	0.7%	P	P			
CLOBAZAM TABLET (ORAL)	0.8%	P	P			
PHENYTOIN CAPSULE (ORAL)	0.8%	P	P			
ETHOSUXIMIDE CAPSULE (AG) (ORAL)	0.0%	P	P			
PHENYTOIN CHEWABLE TABLET (ORAL)	0.1%	P	P			
DIVALPROEX SPRINKLE (AG) (ORAL)	0.0%	P	P			
PHENOBARBITAL TABLET (ORAL)	0.7%	P	P			
CLONAZEPAM ODT (ORAL)	0.2%	NP	NP			
CARBAMAZEPINE CHEWABLE TABLET (ORAL)	0.4%	P	P			
DILANTIN 30 MG CAPSULE (ORAL)	0.0%	P	P			
LAMICTAL TABLET DOSE PACK (ORAL)	0.0%	P	P			
TOPIRAMATE SPRINKLE (ORAL)	0.3%	P	P			
PHENOBARBITAL ELIXIR (ORAL)	0.3%	P	P			
PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (O	0.1%	P	P			
CARBAMAZEPINE SUSPENSION (ORAL)	0.0%	NP	NP			
DIVALPROEX SPRINKLE (ORAL)	1.3%	P	P			
ETHOSUXIMIDE CAPSULE (ORAL)	0.2%	P	P			
ETHOSUXIMIDE SYRUP (ORAL)	0.2%	P	P			
DILANTIN INFATAB (ORAL)	0.0%	P	P			
PHENYTEK (ORAL)	0.0%	NP	NP			
CARBAMAZEPINE XR (ORAL)	0.2%	P	P			
CARBAMAZEPINE XR (AG) (ORAL)	0.3%	P	P			
OXCARBAZEPINE SUSPENSION (ORAL)	0.6%	P	P			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.9%	P	P			
LAMICTAL ODT DOSE PACK (ORAL)	0.0%	NP	NP			
EQUETRO (ORAL)	0.0%	NP	NP			
QUDEXY XR (ORAL)	0.0%	NP	NP			
CLOBAZAM SUSPENSION (ORAL)	0.4%	P	P			
BANZEL TABLET (ORAL)	0.2%	NP	NP			
LAMOTRIGINE XR (ORAL)	0.7%	NP	NP			
DIAZEPAM DEVICE (AG) (RECTAL)	0.4%	P	P			
OXTELLAR XR (ORAL)	0.2%	NP	NP			
DIAZEPAM (AG) (RECTAL)	0.0%	P	P			
FYCOMPA TABLET (ORAL)	0.2%	NP	NP			
VIMPAT TABLET (ORAL)	1.3%	NP	NP			
VIMPAT SOLUTION (ORAL)	0.2%	NP	NP			
TIAGABINE (ORAL)	0.0%	NP	NP			
LAMOTRIGINE ODT DOSE PACK (ORAL)	0.0%	NP	NP			
FELBAMATE TABLET (ORAL)	0.3%	P	P			
LAMICTAL ODT (ORAL)	0.0%	NP	NP			
NAYZLAM (NASAL)	0.0%	NR	NP			
TROKENDI XR (ORAL)	0.3%	NP	NP			
LAMICTAL XR (ORAL)	0.1%	NP	NP			
SPRITAM (ORAL)	0.0%	NP	NP			
LAMOTRIGINE ODT (ORAL)	0.1%	NP	NP			
LAMOTRIGINE TABLET DOSE PACK (ORAL)	0.0%	P	P			
BANZEL SUSPENSION (ORAL)	0.1%	NP	NP			
FYCOMPA SUSPENSION (ORAL)	0.0%	NP	NP			
LAMICTAL XR DOSE PACK (ORAL)	0.0%	NP	NP			
TRILEPTAL SUSPENSION (ORAL)	0.0%	NP	NP			
APTOM (ORAL)	0.1%	NP	NP			
FELBAMATE SUSPENSION (ORAL)	0.2%	P	P			
BRIVIACT TABLET (ORAL)	0.2%	NP	NP			
SYMPAZAN (ORAL)	0.0%	NR	NP			
BRIVIACT SOLUTION (ORAL)	0.0%	NP	NP			
EPIDIOLEX (ORAL)	0.4%	NR	NP			
SABRIL POWDER PACK (ORAL)	0.0%	P	P			
SABRIL TABLET (ORAL)	0.0%	P	P			
DIACOMIT CAPSULE (ORAL)	0.0%	NR	NP			
DIACOMIT POWDER PACK (ORAL)	0.0%	NR	NP			
VIGADRONE 500 MG POWDER PACKET	0.0%	NP	NP			
VIGABATRIN 500 MG POWDER PACKET	0.0%	NP	NP			
VIGABATRIN TABLET (ORAL)	0.0%	NR	NP			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – John Fangman
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
ANTIDEPRESSANTS, OTHER						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
APLENZIN (ORAL)	0.0%	NP	NP			
MARPLAN (ORAL)	0.0%	P	P			
TRAZODONE (ORAL)	27.6%	P	P			
VENLAFAXINE ER CAPSULES (ORAL)	20.4%	P	P			
MIRTAZAPINE TABLET (ORAL)	12.2%	P	P			
BUPROPION SR (ORAL)	7.6%	P	P			
VENLAFAXINE (ORAL)	1.8%	P	P			
BUPROPION (ORAL)	1.7%	P	P			
BUPROPION XL (ORAL)	22.8%	P	P			
MIRTAZAPINE ODT (ORAL)	0.2%	P	P			
DESVENLAFAXINE ER (PRISTIQ) (AG) (ORAL)	0.3%	P	P			
DESVENLAFAXINE ER (PRISTIQ) (ORAL)	2.4%	P	P			
TRINTELLIX (ORAL)	1.2%	NP	NP			
VIBRYD (ORAL)	1.1%	NP	NP			
PHENELZINE (ORAL)	0.0%	P	P			
FETZIMA (ORAL)	0.3%	NP	NP			
NEFAZODONE (ORAL)	0.1%	NP	NP			
BUPROPION XL (FORFIVO XL) (AG) (ORAL)	0.0%	NR	NP			
DESVENLAFAXINE ER (NO BRAND) (ORAL)	0.0%	NP	NP			
FORFIVO XL (ORAL)	0.0%	NP	NP			
VIBRYD DOSE PACK (ORAL)	0.0%	NP	NP			
DESVENLAFAXINE ER (KHEDEZLA) (AG) (ORAL)	0.0%	NP	NP			
NARDIL (ORAL)	0.0%	P	P			
TRANLYCPROMINE SULFATE (ORAL)	0.0%	P	P			
EMSAM (TRANSDERMAL)	0.0%	NP	NP			
VENLAFAXINE ER TABLETS (AG) (ORAL)	0.0%	NP	NP			
VENLAFAXINE ER TABLETS (ORAL)	0.0%	NP	NP			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
ANTIHYPERTENSIVES						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALLOPURINOL (ORAL)	77.3%	P	P			
PROBENECID (ORAL)	0.8%	P	P			
PROBENECID / COLCHICINE (ORAL)	2.6%	P	P			
MITIGARE (ORAL)	0.0%	NP	NP			
MITIGARE (ORAL)	0.0%	NP	Alternate			
ULORIC (ORAL)	6.0%	NP	NP			
COLCHICINE CAPSULE (AG) (ORAL)	11.6%	P	P			
COLCHICINE TABLET (AG) (ORAL)	0.9%	NP	NP			
COLCRYS (ORAL)	0.1%	NP	NP			
FEBUXOSTAT (ORAL)	0.7%	NR	NP			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
ANTIPARKINSON'S AGENTS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZILECT (ORAL)	0.0%	NP	NP			
ZELAPAR (ORAL)	0.0%	NP	NP			
PRAMIPEXOLE (ORAL)	17.0%	P	P			
ROPINIROLE (ORAL)	28.8%	P	P			
AMANTADINE SYRUP (ORAL)	0.2%	P	P			
BENZTROPINE (ORAL)	31.6%	P	P			
TRIHXYPHENIDYL TABLET (ORAL)	4.4%	P	P			
CARBIDOPA / LEVODOPA (ORAL)	9.2%	P	P			
CARBIDOPA / LEVODOPA ER (ORAL)	2.0%	P	P			
TRIHXYPHENIDYL ELXIR (ORAL)	0.2%	P	P			
NEUPRO (TRANSFORM)	0.4%	NP	NP			
AMANTADINE CAPSULE (ORAL)	2.9%	P	P			
CARBIDOPA / LEVODOPA ODT (ORAL)	0.1%	P	P			
SELEGILINE CAPSULE (ORAL)	0.1%	P	P			
AMANTADINE TABLET (ORAL)	1.4%	P	P			
SELEGILINE TABLET (ORAL)	0.0%	P	P			
ROPINIROLE ER (ORAL)	0.1%	NP	NP			
CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)	0.2%	P	P			
ENTACAPONE (ORAL)	0.1%	NP	NP			
BROMOCRIPTINE (ORAL)	0.8%	P	P			
STALEVO (ORAL)	0.0%	NP	NP			
RASAGILINE (ORAL)	0.2%	NP	NP			
PRAMIPEXOLE ER (ORAL)	0.0%	NP	NP			
CARBIDOPA (ORAL)	0.1%	P	P			
RYTARY (ORAL)	0.1%	NP	NP			
COMTAN (ORAL)	0.0%	NP	NP			
OSMOLEX ER (ORAL)	0.0%	NP	NP			
INBRUJA (INHALATION)	0.0%	NR	NP			
XADAGO (ORAL)	0.0%	NP	NP			
GOCOVRI (ORAL)	0.0%	NP	NP			
TOLCAPONE (ORAL)	0.0%	NP	NP			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
ANTIPSORIATICS, TOPICAL						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TACLONEX SCALP (TOPICAL)	11.1%	P	P			
VECTICAL (TOPICAL)	0.9%	P	P			
SORILUX (TOPICAL)	0.0%	NP	NP			
CALCIPOTRIENE SOLUTION (TOPICAL)	10.1%	P	P			
CALCIPOTRIENE CREAM (TOPICAL)	50.0%	P	P			
ENSTLAR (TOPICAL)	3.2%	NP	NP			
CALCIPOTRIENE OINTMENT (TOPICAL)	22.5%	P	P			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (TOPICAL)	0.3%	NP	NP			
CALCITRIOL OINTMENT (TOPICAL)	0.0%	NP	NP			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (AG) (TOPICAL)	1.6%	NP	NP			
DUOBRII (TOPICAL)	0.3%	NR	NP			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – Roseanne Barber
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid ANTIPSYCHOTICS		Recommendations				
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOZAPINE (AG) (ORAL)	0.0%	P	P			
RISPERIDONE TABLET (ORAL)	14.9%	P	P			
QUETIAPINE TABLETS (ORAL)	27.1%	P	P			
OLANZAPINE TABLET (ORAL)	8.4%	P	P			
ARIPIPRAZOLE TABLET (ORAL)	19.5%	P	P			
QUETIAPINE ER (AG) (ORAL)	0.0%	P	P			
HALOPERIDOL LACTATE CONC (ORAL)	0.2%	P	P			
ZIPRASIDONE CAPSULE (ORAL)	4.4%	P	P			
QUETIAPINE ER (ORAL)	1.6%	P	P			
RISPERIDONE SOLUTION (ORAL)	0.5%	P	P			
PERPHENAZINE (ORAL)	0.3%	P	P			
OLANZAPINE ODT (ORAL)	0.6%	P	P			
HALOPERIDOL (ORAL)	2.1%	P	P			
CLOZAPINE (ORAL)	2.4%	P	P			
LOXAPINE (ORAL)	0.3%	P	P			
MOLINDONE (ORAL)	0.0%	NP	NP			
HALOPERIDOL DECANOATE (INJECTION)	0.9%	P	P			
TRIFLUOPERAZINE (ORAL)	0.1%	P	P			
FLUPHENAZINE DECANOATE (INJECTION)	0.3%	P	P			
THIORIDAZINE (ORAL)	0.0%	NP	NP			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.0%	P	P			
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.0%	P	P			
RISPERIDONE ODT (ORAL)	0.3%	P	P			
PIMOZIDE (ORAL)	0.1%	P	P			
THIOTHIXENE (ORAL)	0.0%	P	P			
ADASUVE (INHALATION)	0.0%	NP	NP			
FLUPHENAZINE TABLET (ORAL)	0.7%	P	P			
LATUDA (ORAL)	6.6%	P	P			
OLANZAPINE/FLUOXETINE (ORAL)	0.0%	NP	NP			
SAPHRIS (SUBLINGUAL)	0.4%	NP	NP			
HALDOL DECANOATE (INTRAMUSC)	0.0%	P	P			
SYMBYAX (ORAL)	0.0%	NP	NP			
FAZACLO (ORAL)	0.0%	NP	NP			
CHLORPROMAZINE (ORAL)	0.5%	P	P			
PALIPERIDONE (AG) (ORAL)	0.0%	NP	NP			
PALIPERIDONE (ORAL)	0.0%	NP	NP			
FANAPT TABLET (ORAL)	0.1%	NP	NP			
CLOZAPINE ODT (ORAL)	0.1%	NP	NP			
RISPERDAL CONSTA (INTRAMUSC.)	0.8%	P	P			
ARIPIPRAZOLE SOLUTION (ORAL)	0.1%	P	P			
VRAYLAR (ORAL)	1.6%	NP	NP			
REXULTI (ORAL)	1.1%	NP	NP			
ZYPREXA RELPREVV (INTRAMUSC)	0.0%	P	P			
INVEGA SUSTENNA (INTRAMUSC)	2.0%	P	P			
PERSERIS (SUBCUTANEOUS)	0.0%	NP	NP			
ARISTADA INITIO (INTRAMUSC)	0.0%	P	P			
ABILIFY MAINTENA (INTRAMUSC.)	0.9%	P	P			
ARISTADA (INTRAMUSC)	0.7%	P	P			
ARIPIPRAZOLE ODT (ORAL)	0.2%	P	P			
CLOZAPINE ODT (AG) (ORAL)	0.0%	NP	NP			
ABILIFY MYCITE (ORAL)	0.0%	NR	NP			
NUPLAZID CAPSULE (ORAL)	0.0%	NP	NP			
INVEGA TRINZA (INTRAMUSC)	0.2%	P	P			
VERSACLOZ (ORAL)	0.0%	NP	NP			
NUPLAZID TABLET (ORAL)	0.0%	NP	NP			

- Discussion: Michael Witkovsky indicated that during the closed session, the Committee discussed the technology used in the new Abilify MyCite product, noting that it is an intriguing option and may be of use among other populations, but does not make sense clinically at this time.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid BRONCHODILATORS, BETA AGONIST		Recommendations				
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SEREVENT (INHALATION)	0.3%	P	P			
STRIVERDI RESPIMAT (INHALATION)	0.0%	NP	NP			
ARCAPTA NEOHALER (INHALATION)	0.0%	NP	NP			
ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)	10.1%	P	P			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.0%	P	P			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	0.9%	P	P			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.1%	P	P			
LEVALBUTEROL NEB SOLN (INHALATION)	0.2%	NP	NP			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.0%	NP	NP			
METAPROTERENOL SYRUP (ORAL)	0.0%	NP	NP			
ALBUTEROL SYRUP (ORAL)	0.1%	P	P			
ALBUTEROL ER (ORAL)	0.0%	P	P			
TERBUTALINE (AG) (ORAL)	0.0%	P	P			
TERBUTALINE (ORAL)	0.0%	P	P			
ALBUTEROL TABLET (ORAL)	0.0%	P	P			
PERFORMIST (INHALATION)	0.1%	NP	NP			
BROVANA (INHALATION)	0.1%	NP	NP			
PROAIR HFA (INHALATION)	80.5%	P	P			
XOPENEX HFA (INHALATION)	0.1%	NP	NP			
PROAIR RESPCLICK (INHALATION)	0.0%	NP	NP			
ALBUTEROL HFA (PROVENTIL) (AG) (INHALATION)	1.1%	NR	NP			
ALBUTEROL HFA (PROAIR) (AG) (INHALATION)	0.0%	NR	NP			
ALBUTEROL HFA (VENTOLIN) (AG) (INHALATION)	0.0%	NR	NP			
LEVALBUTEROL HFA (AG) (INHALATION)	0.3%	NP	NP			
VENTOLIN HFA (INHALATION)	0.5%	NP	NP			
PROVENTIL HFA (INHALATION)	5.6%	P	P			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid COPD AGENTS		Recommendations				
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SPIRIVA (INHALATION)	44.4%	P	P			
ATROVENT HFA (INHALATION)	3.2%	P	P			
IPRATROPIUM NEBULIZER (INHALATION)	1.4%	P	P			
SPIRIVA RESPIMAT (INHALATION)	2.6%	NP	NP			
IPRATROPIUM / ALBUTEROL (INHALATION)	18.5%	P	P			
COMBIVENT RESPIMAT (INHALATION)	19.1%	P	P			
BEVESPI AEROSPHERE (INHALATION)	3.1%	P	P			
STIOLTO RESPIMAT (INHALATION)	2.7%	P	P			
ANORO ELLIPTA (INHALATION)	1.9%	NP	NP			
INCRUSE ELLIPTA (INHALATION)	0.9%	NP	NP			
DALIRESP (ORAL)	1.9%	NP	NP			
UTIBRON NEOHALER (INHALATION)	0.0%	NP	NP			
TUDORZA PRESSAIR (INHALATION)	0.3%	NP	NP			
SEEBRI NEOHALER (INHALATION)	0.0%	NP	NP			
YUPELRI (INHALATION)	0.0%	NR	NP			
LONHALA MAGNAIR (INHALATION)	0.0%	NP	NP			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
 - Second – Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
CYTOKINE AND CAM ANTAGONISTS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OTEZLA (ORAL)	8.0%	P	P			
XELJANZ (ORAL)	1.5%	NP	NP			
ENBREL MINI CARTRIDGE (SUBCUTANE.)	1.5%	P	P			
ENBREL KIT (INJECTION)	0.4%	P	P			
HUMIRA PEN KIT (INJECTION)	0.0%	P	Alternate			
ENBREL SYRINGE (INJECTION)	2.3%	P	P			
HUMIRA KIT (INJECTION)	0.0%	P	Alternate			
ENBREL PEN (INJECTION)	11.5%	P	P			
HUMIRA PEN KIT (INJECTION)	0.0%	P	Alternate			
HUMIRA KIT (INJECTION)	0.0%	P	Alternate			
KINERET (INJECTION)	0.1%	NP	NP			
HUMIRA PEN KIT (INJECTION)	52.5%	P	P			
HUMIRA KIT (INJECTION)	5.3%	P	P			
ORENCIA SYRINGE (SUBCUTANE.)	0.5%	NP	NP			
ORENCIA CLICKJECT (SUBCUTANE.)	1.8%	NP	NP			
CIMZIA SYRINGE KIT (INJECTION)	2.2%	NP	NP			
ACTEMRA SYRINGE (SUBCUTANE.)	1.1%	NP	NP			
XELJANZ XR (ORAL)	1.3%	NP	NP			
OLUMIANT (ORAL)	0.2%	NP	NP			
SIMPONI PEN INJECTOR (INJECTION)	0.5%	NP	NP			
ACTEMRA PEN (SUBCUTANEOUS)	0.2%	NR	NP			
KEVZARA PEN (SUBCUTANEOUS)	0.1%	NP	NP			
TALTZ AUTOINJECTOR (SUBCUTANE.)	1.0%	NP	NP			
KEVZARA SYRINGE (SUBCUTANEOUS)	0.1%	NP	NP			
CIMZIA KIT (INJECTION)	0.0%	NP	NP			
COSENTYX PEN INJECTER (SUBCUTANE.)	3.6%	NP	NP			
COSENTYX SYRINGE (SUBCUTANE.)	0.4%	NP	NP			
TALTZ SYRINGE (SUBCUTANE.)	0.1%	NP	NP			
SILIQ (SUBCUTANE.)	0.1%	NP	NP			
SIMPONI SYRINGE (INJECTION)	0.1%	NP	NP			
RINVOQ ER (ORAL)	0.0%	NR	NP			
TREMFYA AUTOINJECTOR (SUBCUTANE.)	0.1%	NR	NP			
TREMFYA SYRINGE (SUBCUTANE.)	0.3%	NP	NP			
STELARA SYRINGE (INJECTION)	3.2%	NP	NP			
STELARA VIAL (INJECTION)	0.0%	NP	NP			
SKYRIZI (SUBCUTANEOUS)	0.0%	NR	NP			

- Discussion: Kelsey Brundage thanked John Fangman for his recommendation during closed session to engage rheumatologists in discussion of access to medications in this class, similar to discussion that occurred between the Department and providers related to Hepatitis C medications.
- John Fangman made a motion to accept staff recommendations as presented.
 - Second – Steve Maiké
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
EPINEPHRINE, SELF-INJECTED						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPINEPHRINE 0.15 MG (EPIPEN JR) (AG) (INJECTION)	10.2%	P	P			
EPINEPHRINE 0.3 MG (EPIPEN) (AG) (INJECTION)	50.2%	P	P			
EPINEPHRINE 0.15 MG (ADRENACLICK) (AG) (INJECTION)	1.8%	P	NP			
EPIPEN JR (INTRAMUSC)	3.5%	P	NP			
SYMJEPI (INJECTION)	0.0%	NR	NP			
EPINEPHRINE 0.3 MG (ADRENACLICK) (AG) (INJECTION)	9.3%	P	NP			
EPIPEN (INTRAMUSC)	3.2%	P	NP			
EPINEPHRINE 0.15 MG (EPIPEN JR) (INJECTION)	0.0%	P	NP			
EPINEPHRINE 0.3 MG AUTO INJECTOR (INJECTION)	21.8%	P	NP			

- Discussion: Michael Witkovsky thanked other Committee members for the discussion and education related to drug costs in this class during the closed session.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RETACRIT (INJECTION)	0.7%	P	NP			
EPOGEN (INJECTION)	0.0%	NP	P			
ARANESP DISP SYRIN (INJECTION)	54.6%	P	P			
ARANESP VIAL (INJECTION)	6.9%	P	P			
PROCRIT (INJECTION)	37.8%	P	NP			
MIRCERA (INJECTION)	0.0%	NP	NP			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
GLUCOCORTICIDS, INHALED						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ADVAIR HFA (INHALATION)	1.9%	P	P			
SYMBICORT (INHALATION)	26.9%	P	P			
DULERA (INHALATION)	6.5%	P	P			
AIRDUO RESPICLICK (INHALATION)	0.0%	NP	NP			
BREO ELLIPTA (INHALATION)	1.2%	NP	NP			
FLUTICASONE/SALMETEROL (AIRDUO) (AG) (INHALATION)	0.0%	NR	NP			
FLUTICASONE/SALMETEROL (ADVAIR) (AG) (INHALATION)	0.0%	NR	NP			
ADVAIR DISKUS (INHALATION)	31.1%	P	P			
Wixela INHUB (INHALATION)	0.0%	NR	NP			
TRELEGY ELLIPTA (INHALATION)	0.8%	NP	NP			
ASMANEX (INHALATION)	1.5%	P	P			
FLOVENT DISKUS (INHALATION)	0.0%	NP	NP			
FLOVENT HFA (INHALATION)	25.4%	P	P			
PULMICORT FLEXHALER (INHALATION)	2.1%	P	P			
QVAR (INHALATION)	0.0%	NP	NP			
ARNUIITY ELLIPTA (INHALATION)	0.1%	NP	NP			
ASMANEX HFA (INHALATION)	0.1%	NP	NP			
QVAR REDIHALER (INHALATION)	0.5%	NP	NP			
BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)	1.6%	P	P			
ALVESCO (INHALATION)	0.1%	NP	NP			
BUDESONIDE 1 MG RESPULES (INHALATION)	0.2%	P	P			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid GLUCOCORTICIDS, ORAL		Recommendations				
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RAYOS TABLET DR (ORAL)	0.0%	NP	NP			
PREDNISOLONE SOLUTION (ORAL)	3.2%	P	P			
PREDNISONE TABLET (ORAL)	68.3%	P	P			
MEDROL TABLET (ORAL)	0.0%	NP	NP			
METHYLPREDNISOLONE TAB DS PK (ORAL)	11.4%	P	P			
PREDNISOLONE SODIUM PHOSPHATE (ORAL)	5.8%	P	P			
DEXAMETHASONE TABLET (ORAL)	5.3%	P	P			
METHYLPREDNISOLONE 4 MG TABLET (ORAL)	0.4%	P	P			
DEXAMETHASONE ELIXIR (ORAL)	0.2%	P	P			
METHYLPREDNISOLONE 16 MG TABLET (ORAL)	0.0%	P	P			
HYDROCORTISONE (ORAL)	2.9%	P	P			
PREDNISONE TAB DS PK (ORAL)	0.0%	P	P			
DEXAMETHASONE SOLUTION (ORAL)	0.2%	P	P			
DEXAMETHASONE INTENSOL (ORAL)	0.3%	P	P			
METHYLPREDNISOLONE 8 MG TABLET (ORAL)	0.0%	P	P			
METHYLPREDNISOLONE 32 MG TABLET (ORAL)	0.2%	P	P			
PREDNISONE SOLUTION (ORAL)	0.2%	P	P			
DEXPAK (ORAL)	0.0%	NP	NP			
CORTISONE (ORAL)	0.0%	NP	NP			
BUDESONIDE EC (ORAL)	1.4%	P	P			
PREDNISOLONE SODIUM PHOSPHATE SOLUTION (VERIPRED) (ORAL)	0.0%	NP	NP			
PREDNISOLONE SODIUM PHOSPHATE SOLUTION (MILLIPRED) (ORAL)	0.0%	NP	NP			
PREDNISOLONE SODIUM PHOSPHATE ODT (ORAL)	0.0%	P	P			
PREDNISONE INTENSOL (ORAL)	0.0%	P	P			
TAPERDEX (ORAL)	0.0%	NP	NP			
DEXAMETHASONE TAB DS PK (ORAL)	0.0%	NP	NP			
PREDNISOLONE SODIUM PHOSPHATE ODT (AG) (ORAL)	0.1%	P	P			
MILLIPRED DP TAB DS PK (ORAL)	0.0%	NP	NP			
DXEVO (ORAL)	0.0%	NR	NP			
MILLIPRED TABLET (ORAL)	0.0%	NP	NP			
EMFLAZA SUSPENSION (ORAL)	0.0%	NP	NP			
EMFLAZA TABLET (ORAL)	0.0%	NP	NP			

- Discussion: Kelsey Brundage stated that during the closed session, the Committee discussed recent studies related to Emflaza. The Department is reviewing these studies and evaluating their possible impact on current prior authorization criteria for the medication.
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid			Recommendations			
IMMUNOMODULATORS, ATOPIC DERMATITIS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PIMECROLIMUS (AG) (TOPICAL)	0.0%	NR	NP			
PROTOPIC (TOPICAL)	28.4%	P	P			
ELIDEL (TOPICAL)	59.3%	P	P			
TACROLIMUS (AG) (TOPICAL)	0.5%	NP	NP			
EUCRISA (TOPICAL)	0.4%	NP	NP			
EUCRISA (TOPICAL)	0.0%	NP	Alternate			
PIMECROLIMUS (TOPICAL)	0.0%	NR	NP			
TACROLIMUS (TOPICAL)	0.1%	NP	NP			
DUPIXENT (SUBCUTANEOUS)	11.3%	NP	NP			

- Discussion: Kevin Izard stated that the Committee discussed the step through requirements for Eucrisa during the closed session, and trying a topical steroid and topical calcineurin inhibitor and the related time this requires before accessing Eucrisa is reasonable.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid			Recommendations			
INTRANASAL RHINITIS AGENTS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZELASTINE (ASTEPRO) (AG) (NASAL)	0.0%	NP	NP			
ASTEPRO (NASAL)	0.0%	NP	NP			
AZELASTINE (ASTELIN) (NASAL)	2.6%	P	P			
AZELASTINE (ASTEPRO) (NASAL)	0.0%	NP	NP			
OLOPATADINE (AG) (NASAL)	0.1%	P	NP			
OLOPATADINE (NASAL)	1.0%	P	NP			
IPRATROPIUM (NASAL)	2.3%	P	P			
DYMISTA (NASAL)	0.2%	NP	NP			
FLUTICASONE (NASAL)	92.0%	P	P			
BECONASE AQ (NASAL)	1.0%	P	P			
QNASL 80 (NASAL)	0.2%	NP	NP			
MOMETASONE (AG) (NASAL)	0.0%	NP	NP			
MOMETASONE (NASAL)	0.6%	NP	NP			
OMNARIS (NASAL)	0.0%	NP	NP			
FLUNISOLIDE (NASAL)	0.0%	NP	NP			
QNASL 40 (NASAL)	0.0%	NP	NP			
ZETONNA (NASAL)	0.0%	NP	NP			
NASONEX (NASAL)	0.1%	NP	NP			
XHANCE (NASAL)	0.0%	NP	NP			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – John Fangman
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
NEUROPATHIC PAIN						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SAVELLA (ORAL)	0.6%	P	P			
SAVELLA DOSE PACK (ORAL)	0.0%	P	P			
LYRICA CAPSULE (ORAL)	13.0%	P	P			
GRALISE (ORAL)	0.0%	NP	NP			
GABAPENTIN CAPSULE (ORAL)	41.1%	P	P			
CAPSAICIN OTC (TOPICAL)	0.2%	P	P			
DULOXETINE (CYMBALTA) (ORAL)	23.3%	P	P			
HORIZANT (ORAL)	0.0%	NP	NP			
GABAPENTIN TABLET (ORAL)	14.5%	P	P			
PREGABALIN CAPSULE (AG) (ORAL)	0.0%	NR	P			
PREGABALIN CAPSULE (ORAL)	0.1%	NR	P			
PREGABALIN SOLUTION (ORAL)	0.0%	NR	P			
GABAPENTIN SOLUTION (ORAL)	0.6%	P	P			
PREGABALIN SOLUTION (AG) (ORAL)	0.0%	NR	P			
LIDOCAINE (TOPICAL)	5.7%	P	P			
LIDOCAINE (AG) (TOPICAL)	0.9%	P	P			
ZTLIDO (TOPICAL)	0.0%	NR	NP			
ZTLIDO (TOPICAL)	0.0%	NR	Alternate			
DULOXETINE (IRENKA) (ORAL)	0.1%	NP	NP			
LYRICA SOLUTION (ORAL)	0.0%	P	P			
LYRICA CR (ORAL)	0.0%	NP	NP			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
NSAIDS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NAPROXEN EC (AG) (ORAL)	0.0%	NR	NP			
DUEXIS (ORAL)	0.0%	NP	NP			
PENNSAID PUMP (TOPICAL)	0.0%	NP	NP			
VIMOVO (ORAL)	0.0%	NP	NP			
CELECOXIB (AG) (ORAL)	0.1%	P	P			
VOLTAREN (TOPICAL)	8.9%	P	P			
MELOXICAM TABLET (ORAL)	14.6%	P	P			
IBUPROFEN TABLET OTC (ORAL)	1.7%	P	P			
NAPROXEN SODIUM OTC (ORAL)	0.5%	P	P			
IBUPROFEN TABLET (ORAL)	32.6%	P	P			
NAPROXEN TABLET (ORAL)	13.4%	P	P			
IBUPROFEN SUSPENSION OTC (ORAL)	4.2%	P	P			
INDOMETHACIN CAPSULE (ORAL)	1.3%	P	P			
IBUPROFEN TAB CHEW OTC (ORAL)	0.0%	P	P			
CELECOXIB (ORAL)	3.7%	P	P			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.0%	P	P			
INDOMETHACIN CAPSULE ER (ORAL)	0.0%	NP	NP			
IBUPROFEN SUSPENSION (ORAL)	6.4%	P	P			
DICLOFENAC SODIUM (ORAL)	7.9%	P	P			
SULINDAC (ORAL)	0.3%	P	P			
NABUMETONE (ORAL)	1.3%	P	P			
NAPROXEN EC (ORAL)	0.2%	P	P			
KETOROLAC (ORAL)	2.1%	P	P			
FLURBIPROFEN (ORAL)	0.1%	P	P			
ZIPSOR (ORAL)	0.0%	NP	NP			
NAPROXEN SODIUM (ORAL)	0.0%	NP	NP			
PIROXICAM (ORAL)	0.0%	NP	NP			
DICLOFENAC POTASSIUM (ORAL)	0.1%	P	P			
DICLOFENAC GEL (TOPICAL)	0.0%	NP	NP			
DICLOFENAC SOLUTION (TOPICAL)	0.0%	NP	NP			
ETODOLAC (ORAL)	0.0%	NP	NP			
DIFLUNISAL (ORAL)	0.0%	NP	NP			
MEFENAMIC ACID (ORAL)	0.0%	NP	NP			
DICLOFENAC SR (ORAL)	0.2%	P	P			
OXAPROZIN (ORAL)	0.0%	NP	NP			
INDOCIN (RECTAL)	0.0%	NP	NP			
DICLOFENAC SODIUM/MISOPROSTOL (ORAL)	0.0%	NP	NP			
KETOPROFEN (ORAL)	0.0%	P	P			
ZORVOLEX (ORAL)	0.0%	NP	NP			
NAPROXEN SUSPENSION (ORAL)	0.0%	NP	NP			
INDOCIN SUSPENSION (ORAL)	0.0%	NP	NP			
TIVORBEX (ORAL)	0.0%	NP	NP			
QMIIZ ODT (ORAL)	0.0%	NR	NP			
SPRIX (NASAL)	0.0%	NP	NP			
MECLOFENAMATE (ORAL)	0.0%	NP	NP			
TOLMETIN SODIUM TABLET (ORAL)	0.0%	NP	NP			
NAPRELAN (ORAL)	0.0%	NP	NP			
FENOPROFEN (ORAL)	0.0%	NP	NP			
KETOPROFEN ER (ORAL)	0.0%	NP	NP			
TOLMETIN SODIUM CAPSULE (ORAL)	0.0%	NP	NP			
ETODOLAC TAB SR (ORAL)	0.0%	NP	NP			
DICLOFENAC PATCH (AG) (TRANSDERMAL)	0.0%	NR	NP			
NAPROXEN CR (AG) (ORAL)	0.0%	NP	NP			
FLECTOR (TOPICAL)	0.0%	NP	NP			
NALFON (ORAL)	0.0%	NP	NP			
VMLODEX (ORAL)	0.0%	NP	NP			
ARTHROTEC (ORAL)	0.0%	NP	NP			
NAPROXEN CR (ORAL)	0.0%	NP	NP			
FENOPROFEN (AG) (ORAL)	0.0%	NP	NP			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
OPHTHALMICS, ANTI-INFLAMMATORIES						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACUVAIL (OPHTHALMIC)	0.0%	NP	NP			
ILEVRO (OPHTHALMIC)	2.4%	P	P			
DICLOFENAC (OPHTHALMIC)	0.0%	NP	NP			
KETOROLAC (OPHTHALMIC)	14.2%	P	P			
NEVANAC (OPHTHALMIC)	0.0%	NP	NP			
FLURBIPROFEN (OPHTHALMIC)	0.1%	P	P			
KETOROLAC LS (OPHTHALMIC)	5.1%	P	P			
PROLENSA (OPHTHALMIC)	0.2%	NP	NP			
BROMFENAC (OPHTHALMIC)	0.0%	NP	NP			
BROMSITE (OPHTHALMIC)	0.0%	NP	NP			
LOTEMAX DROPS (OPHTHALMIC)	4.1%	P	P			
PRED MILD (OPHTHALMIC)	0.1%	P	P			
FML FORTE (OPHTHALMIC)	0.2%	P	P			
FLAREX (OPHTHALMIC)	0.0%	P	P			
MAXIDEX (OPHTHALMIC)	0.3%	P	P			
FLUOROMETHOLONE (OPHTHALMIC)	7.9%	P	P			
FML S.O.P. (OPHTHALMIC)	0.0%	P	NP			
LOTEMAX OINTMENT (OPHTHALMIC)	0.0%	NP	NP			
DUREZOL (OPHTHALMIC)	9.4%	P	P			
PREDNISOLONE ACETATE (OPHTHALMIC)	52.3%	P	P			
DEXAMETHASONE (OPHTHALMIC)	3.1%	P	P			
PREDNISOLONE SOD PHOSPHATE (OPHTHALMIC)	0.2%	P	P			
LOTEMAX GEL (OPHTHALMIC)	0.2%	NP	NP			
INVELTYS (OPHTHALMIC)	0.0%	NR	NP			
FML (OPHTHALMIC)	0.0%	NP	NP			
LOTEPREDNOL DROPS (OPHTHALMIC)	0.0%	NR	NP			
LOTEPREDNOL DROPS (AG) (OPHTHALMIC)	0.1%	NR	NP			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second – Kevin Izard
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RESTASIS (OPHTHALMIC)	93.7%	P	P			
RESTASIS MULTIDOSE (OPHTHALMIC)	0.1%	NP	NP			
XIDRA (OPHTHALMIC)	6.2%	NP	NP			
CEQUA (OPHTHALMIC)	0.0%	NR	NP			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALPHAGAN P 0.1% (OPHTHALMIC)	0.1%	NP	NP			
ALPHAGAN P 0.15% (OPHTHALMIC)	1.6%	P	P			
BRIMONIDINE 0.2% (OPHTHALMIC)	7.6%	P	P			
APRACLONIDINE (OPHTHALMIC)	0.0%	NP	NP			
BRIMONIDINE P 0.15% (OPHTHALMIC)	0.0%	NP	NP			
TIMOLOL (ISTALOL) (AG) (OPHTHALMIC)	0.0%	NP	NP			
TIMOPTIC OCUDOSE (OPHTHALMIC)	0.1%	NP	NP			
COMBIGAN (OPHTHALMIC)	5.2%	P	P			
BETOPTIC S (OPHTHALMIC)	0.2%	P	P			
LEVOBUNOLOL (OPHTHALMIC)	0.4%	P	P			
CARTEOLOL (OPHTHALMIC)	0.1%	P	P			
TIMOLOL (OPHTHALMIC)	14.9%	P	P			
BETAXOLOL (OPHTHALMIC)	0.0%	NP	NP			
ISTALOL (OPHTHALMIC)	0.0%	NP	NP			
TIMOLOL (ISTALOL) (OPHTHALMIC)	0.0%	NP	NP			
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	5.9%	P	P			
DORZOLAMIDE (OPHTHALMIC)	3.9%	P	P			
SIMBRINZA (OPHTHALMIC)	1.6%	P	P			
DORZOLAMIDE/TIMOLOL/PF DROPS (AG) (OPHTHALMIC)	0.1%	P	P			
AZOPT (OPHTHALMIC)	2.3%	P	P			
DORZOLAMIDE/TIMOLOL/PF DROPS (OPHTHALMIC)	0.1%	P	P			
COSOPT PF (OPHTHALMIC)	0.1%	NP	NP			
PILOCARPINE (OPHTHALMIC)	0.5%	P	P			
LUMIGAN 5ML (OPHTHALMIC)	0.1%	NP	NP			
TRAVATAN Z 5 ML (OPHTHALMIC)	1.3%	P	P			
LUMIGAN 2.5ML (OPHTHALMIC)	0.6%	NP	NP			
TRAVATAN Z 2.5 ML (OPHTHALMIC)	12.3%	P	P			
LATANOPROST 2.5 ML (OPHTHALMIC)	40.0%	P	P			
ZIOPTAN (OPHTHALMIC)	0.1%	NP	NP			
XELPROS (OPHTHALMIC)	0.0%	NR	NP			
BIMATOPROST 2.5ML (OPHTHALMIC)	0.0%	NP	NP			
VYZULTA (OPHTHALMIC)	0.2%	NP	NP			
BIMATOPROST 5ML (OPHTHALMIC)	0.0%	NP	NP			
BIMATOPROST 7.5ML (OPHTHALMIC)	0.0%	NP	NP			
RHOPRESSA (OPHTHALMIC)	0.7%	NP	NP			
ROCKLATAN (OPHTHALMIC)	0.0%	NR	NP			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
SEDATIVE HYPNOTICS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SILENOR (ORAL)	0.3%	NP	NP			
ZOLPIDEM (ORAL)	68.2%	P	P			
TEMAZEPAM (ORAL)	10.8%	P	P			
ESZOPICLONE (ORAL)	6.3%	P	P			
ZALEPLON (ORAL)	2.8%	P	P			
ZOLPIMIST (ORAL)	0.0%	NP	NP			
ZOLPIDEM ER (ORAL)	3.4%	NP	NP			
FLURAZEPAM (ORAL)	0.0%	NP	NP			
ROZEREM (ORAL)	4.7%	P	P			
ESTAZOLAM (ORAL)	0.2%	P	P			
TEMAZEPAM 7.5 MG (ORAL)	0.0%	NP	NP			
TRIAZOLAM (ORAL)	1.0%	P	P			
INTERMEZZO (SUBLINGUAL)	0.0%	NP	NP			
BELSOMRA (ORAL)	2.1%	NP	NP			
TEMAZEPAM 22.5 MG (ORAL)	0.0%	NP	NP			
EDLUAR (SUBLINGUAL)	0.0%	NP	NP			
ZOLPIDEM (SUBLINGUAL)	0.0%	NP	NP			
RAMELTEON (ORAL)	0.0%	NR	NP			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid STEROIDS, TOPICAL HIGH		Recommendations			COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec				
KENALOG AEROSOL (TOPICAL)	0.0%	NP	NP				
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	49.4%	P	P				
HALOG OINTMENT (TOPICAL)	0.0%	NP	NP				
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	0.0%	NP	NP				
HALOG CREAM (TOPICAL)	0.0%	NP	NP				
TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)	38.4%	P	P				
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	1.3%	P	P				
BETAMETHASONE VALERATE CREAM (TOPICAL)	3.9%	P	P				
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	0.1%	NP	NP				
BETAMETHASONE VALERATE OINTMENT (TOPICAL)	4.0%	P	P				
BETAMETHASONE VALERATE LOTION (TOPICAL)	1.8%	P	P				
FLUOCINONIDE OINTMENT (TOPICAL)	0.4%	NP	NP				
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	0.2%	NP	NP				
FLUOCINONIDE GEL (TOPICAL)	0.0%	NP	NP				
FLUOCINONIDE SOLUTION (TOPICAL)	0.2%	NP	NP				
FLUOCINONIDE CREAM (TOPICAL)	0.1%	NP	NP				
DESOXIMETASONE SPRAY (TOPICAL)	0.0%	NP	NP				
BETAMETHASONE DIPROPIONATE OINTMENT (TOPICAL)	0.0%	NP	NP				
DESOXIMETASONE OINTMENT (TOPICAL)	0.1%	NP	NP				
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.0%	NP	NP				
BETAMET DIPROP / PROP GLY OINTMENT (TOPICAL)	0.1%	NP	NP				
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.0%	NP	NP				
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.0%	NP	NP				
DESOXIMETASONE CREAM (TOPICAL)	0.1%	NP	NP				
TOPICORT OINTMENT (TOPICAL)	0.0%	NP	NP				
DIPROLENE OINTMENT (TOPICAL)	0.0%	NP	NP				
AMCINONIDE CREAM (TOPICAL)	0.0%	NP	NP				
TRIAMCINOLONE ACETONIDE AEROSOL (TOPICAL)	0.0%	NP	NP				
DESOXIMETASONE GEL (TOPICAL)	0.0%	NP	NP				
AMCINONIDE LOTION (TOPICAL)	0.0%	NP	NP				
SERNIVO SPRAY (TOPICAL)	0.0%	NP	NP				
HALCINONIDE CREAM (TOPICAL)	0.0%	NR	NP				
DIFLORASONE DIACETATE OINTMENT (TOPICAL)	0.0%	NP	NP				
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.0%	NP	NP				
TRIANEX OINTMENT (TOPICAL)	0.0%	NP	NP				
TOPICORT SPRAY (TOPICAL)	0.0%	NP	NP				

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second – Kevin Izard
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
STERIODS, TOPICAL VERY HIGH						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOBEX SHAMPOO (TOPICAL)	1.8%	P	P			
CLOBEX LOTION (TOPICAL)	0.3%	P	P			
CLOBETASOL PROPIONATE OINTMENT (TOPICAL)	43.3%	P	P			
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	22.2%	P	P			
CLOBETASOL PROPIONATE CREAM (TOPICAL)	25.2%	P	P			
HALOBETASOL PROPIONATE CREAM (TOPICAL)	1.4%	P	P			
CLOBETASOL EMOLLIENT (TOPICAL)	1.3%	P	P			
CLOBETASOL PROPIONATE GEL (TOPICAL)	1.2%	P	P			
CLOBETASOL LOTION (TOPICAL)	0.0%	NP	NP			
CLOBETASOL PROPIONATE SPRAY (AG) (TOPICAL)	0.1%	NP	NP			
HALOBETASOL PROPIONATE OINTMENT (TOPICAL)	3.0%	P	P			
CLOBETASOL PROPIONATE SPRAY (TOPICAL)	0.0%	NP	NP			
CLOBETASOL SHAMPOO (TOPICAL)	0.1%	NP	NP			
CLOBETASOL PROPIONATE FOAM (TOPICAL)	0.2%	NP	NP			
BRYHALI (TOPICAL)	0.0%	NR	NP			
LEXETTE (TOPICAL)	0.0%	NR	NP			
ULTRAVATE LOTION (TOPICAL)	0.0%	NP	NP			
APEXICON E (TOPICAL)	0.0%	NP	NP			
OLUX-E (TOPICAL)	0.0%	NP	NP			
HALOBETASOL PROPIONATE FOAM (AG) (TOPICAL)	0.0%	NP	NP			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion
 - Motion passes

Wisconsin Medicaid		Recommendations				
STIMULANTS AND RELATED AGENTS						
Brand Name	Curr. MS	Curr. PDL Status	PDL Rec	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ARMODAFINIL (AG) (ORAL)	0.1%	P	P			
DEXMETHYLPHENIDATE (AG) (ORAL)	0.0%	P	P			
METHYLPHENIDATE (ORAL)	6.3%	P	P			
GUANFACINE ER (ORAL)	10.6%	P	P			
DEXMETHYLPHENIDATE (ORAL)	1.7%	P	P			
FOCALIN XR (ORAL)	5.3%	P	P			
MODAFINIL (ORAL)	0.3%	P	P			
AMPHETAMINE SALT COMBO (ORAL)	11.3%	NP	NP			
ARMODAFINIL (ORAL)	0.0%	P	P			
DEXTROAMPHETAMINE TABLET (ORAL)	0.4%	NP	NP			
METHYLPHENIDATE SOLUTION (AG) (ORAL)	0.0%	P	P			
FOCALIN (ORAL)	0.1%	P	P			
METHYLIN SOLUTION (ORAL)	0.0%	P	P			
VYVANSE CAPSULE (ORAL)	30.2%	P	P			
VYVANSE CHEWABLE TABLET (ORAL)	1.0%	P	P			
METHYLPHENIDATE SOLUTION (ORAL)	0.1%	P	P			
DAYTRANA (TRANSDERMAL)	0.3%	P	P			
METHYLPHENIDATE ER (METADATE ER) (ORAL)	0.8%	P	P			
CONCERTA (ORAL)	10.2%	P	P			
QUILLIVANT XR (ORAL)	0.2%	P	P			
AMPHETAMINE SALT COMBO ER (AG) (ORAL)	8.3%	NP	NP			
AMPHETAMINE SALT COMBO ER (ORAL)	3.2%	NP	NP			
ATOMOXETINE (AG) (ORAL)	2.3%	P	P			
METHYLPHENIDATE CD (AG) (ORAL)	1.5%	P	P			
DEXMETHYLPHENIDATE XR (AG) (ORAL)	0.0%	NP	NP			
ATOMOXETINE (ORAL)	2.1%	P	P			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	0.4%	NP	NP			
METHYLPHENIDATE CD (ORAL)	0.8%	P	P			
METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL)	0.0%	NP	NP			
DEXMETHYLPHENIDATE XR (ORAL)	0.0%	NP	NP			
CLONIDINE ER (ORAL)	1.1%	P	P			
PROCENTRA (ORAL)	0.0%	NP	NP			
METHYLPHENIDATE ER (RITALIN LA) (ORAL)	0.6%	P	P			
EVEKEO ODT (ORAL)	0.0%	NR	NP			
METHYLPHENIDATE CHEWABLE TABLETS (ORAL)	0.2%	P	P			
QUILLICHEW ER (ORAL)	0.4%	P	P			
APTENSIO XR (ORAL)	0.2%	P	P			
MYDAYIS ER (ORAL)	0.1%	NP	NP			
METHYLPHENIDATE ER (CONCERTA) (ORAL)	0.1%	NP	NP			
RITALIN LA (ORAL)	0.0%	NP	NP			
ADZENYS ER SUSPENSION (ORAL)	0.0%	NP	NP			
DEXTROAMPHETAMINE SOLUTION (ORAL)	0.0%	NP	NP			
ADHANSIA XR (ORAL)	0.0%	NR	NP			
ADZENYS XR ODT (ORAL)	0.0%	NP	NP			
COTEMPLA XR ODT (ORAL)	0.0%	NP	NP			
DYANAVEL XR (ORAL)	0.0%	NP	NP			
ZENZEDI (ORAL)	0.0%	NP	NP			
JORNAY PM (ORAL)	0.0%	NR	NP			
METHAMPHETAMINE (ORAL)	0.0%	NP	NP			
EVEKEO (ORAL)	0.0%	NP	NP			
AMPHETAMINE SULFATE (ORAL)	0.0%	NR	NP			
SUNOSI (ORAL)	0.0%	NR	NP			
METHYLPHENIDATE ER 72 MG TABLETS (ORAL)	0.0%	NP	NP			
DEXEDRINE SPANSULE (ORAL)	0.0%	NP	NP			

- Discussion: Kevin Izard stated that the Committee discussed Jornay PM during the closed session, and did not see added efficacy for Jornay PM compared to other methylphenidate products.

In addition, Kevin Izard indicated that keeping Vyvanse as a preferred product and amphetamine salt combo products remaining non-preferred is recommended in-part due to less abuse potential with Vyvanse.

Michael Witkovsky stated that a speaker in the morning session advocated Jornay PM be made a preferred product in-part given the difficulty of early morning symptoms for patients and their families. Witkovsky indicated there are non-pharmacological interventions that may also be beneficial for these members.

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second – Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes